[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"recurrent-pregnancy-loss\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:recurrent-pregnancy-loss":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,48,74,107,137,165,187,226,249,276,304,331],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100590485","right-prefrontal-autonomic-mapping-in-recurrent-pregnancy-loss-with-comorbid-anxiety-100590485",false,"NCT06968026","Right Prefrontal Autonomic Mapping in Recurrent Pregnancy Loss With Comorbid Anxiety","Acute Cardiac Autonomic Responses to High-intensity, Low-frequency, Periodic rTMS Over the Right Dorsolateral Prefrontal Cortex in Women With Recurrent Pregnancy Loss and Comorbid Anxiety Disorders: a Proof-of-concept rTMS-ECG Parameter-finding Trial (NEURO-CARD-rTMS-1)","* Inclusion Criteria:\n\n  * 1)Female, aged 18-45 years, and right-handed.\n  * 2)Diagnosis of recurrent pregnancy loss (RPL), defined as ≥2 consecutive spontaneous miscarriages before 28 weeks of gestation.\n  * 3)Currently non-pregnant, or presenting with a missed abortion (no fetal cardiac activity confirmed by ultrasound).\n  * 4)Hamilton Anxiety Rating Scale (HAMA) score ≥14 and Hamilton Depression Rating Scale (HAMD-17) score ≤17 (to exclude clinically significant depression).\n  * 5)Diagnosis of generalized anxiety disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). The diagnosis will be established through a structured diagnostic interview conducted by a qualified attending-level or senior psychiatrist, either on site or, when on-site assessment cannot be completed, through a secure encrypted video-conferencing platform with multidisciplinary team support.\n* Exclusion Criteria:\n\n  * 1\\) Contraindications to transcranial magnetic stimulation (TMS), including metallic implants or a history of epilepsy;\n  * 2\\) Uncontrolled blood pressure (systolic \\>180 mmHg or \\\u003C90 mmHg);\n  * 3\\) Presence of other major medical conditions, including hyperthyroidism, a history of atrial fibrillation, valvular heart disease, sinus bradycardia, neurological disorders, cerebrovascular disease, or chronic pulmonary disease;\n  * 4)Current use of psychotropic medications at the time of screening, to avoid hemodynamic or autonomic confounding;\n  * 5\\) Clinically significant suicide risk;\n  * 6\\) A current or past diagnosis of other psychiatric disorders, including substance use disorders, schizophrenia, delusional disorder, unspecified psychotic disorder, bipolar disorder, or delirium.","FEMALE","18 Years","45 Years",{"count":20,"type":21},55,"ESTIMATED","INTERVENTIONAL",[24],"NA","Recurrent pregnancy loss is often accompanied by substantial anxiety and may also be associated with autonomic imbalance and increased long-term cardiovascular vulnerability. The present proof-of-concept rTMS-ECG parameter-finding trial will examine whether high-intensity, low-frequency, periodic repetitive transcranial magnetic stimulation (rTMS) delivered over the right dorsolateral prefrontal cortex can induce detectable acute cardiac autonomic responses in women with recurrent pregnancy loss and comorbid anxiety disorders.\n\nA total of 55 women will be enrolled. During a single experimental session, each participant will undergo a stimulation-intensity sweep protocol with six consecutive stimulation cycles at 100%, 110%, 120%, 130%, 140%, and 150% of resting motor threshold. Each cycle will consist of 40 seconds of 1 Hz stimulation followed by a 20-second rest interval, while electrocardiography will be recorded continuously throughout the procedure. The study will evaluate baseline-corrected heart-rate change, wavelet-derived power near the stimulation-cycle frequency, and the rTMS-induced cardiac coupling index across intensity conditions. The goal is to identify the candidate stimulation intensity that produces the most detectable and physiologically consistent acute cardiac autonomic response for transfer to subsequent NEURO-CARD-rTMS studies.",[27,28],"Recurrent Pregnancy Loss","Anxiety Disorders",[30,31,32,33,34],"Recurrent pregnancy loss","anxiety disorders","repetitive transcranial magnetic stimulation","dorsolateral prefrontal cortex","autonomic modulation","RECRUITING","2026-05-22",{"date":38,"type":39},"2026-05-26","ACTUAL",{"date":41,"type":39},"2025-05-16",{"date":43,"type":21},"2026-05-13",{"name":45,"class":46},"Shenyang Jinghua Hospital","INDUSTRY",3,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":17,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100473391","genomic-predictors-of-recurrent-pregnancy-loss-100473391","NCT05444283","Genomic Predictors of Recurrent Pregnancy Loss","Large Scale Genome Sequencing and Integrative Analyses to Define Genomic Predictors of Recurrent Pregnancy Loss","GPRPL","Cohort A - Fetal Intolerome Cohort\n\nInclusion Criteria:\n\n* Women with loss of a current singleton pregnancy at \\\u003C 20 0\u002F7 weeks gestation, documented by ultrasonography or histopathological examination\n* History of one or more prior pregnancy losses\n* Euploid current pregnancy confirmed by karyotype, microarray, or STORK (Short-read Transpore Rapid Karyotyping) sequencing Note: A limited number of aneuploid losses will be included as part of the pilot phase\n\nExclusion Criteria:\n\n* History of parental karyotype abnormalities\n* History of antiphospholipid antibody syndrome\n* Evidence of uncontrolled diabetes\n* Evidence of uncontrolled thyroid disease\n* History of autoimmune disease related to pregnancy loss (e.g., systemic lupus erythematosus, rheumatoid arthritis)\n* History of uterine anomalies\n* History of cervical insufficiency\n\nCohort B - Maternal Effect Gene Cohort\n\nInclusion Criteria:\n\n\\- Women with a history of three or more pregnancy losses of unknown cause, with or without a liveborn child\n\nExclusion Criteria:\n\n\\- Known etiology for pregnancy loss",true,"ALL","50 Years",{"count":60,"type":21},500,"OBSERVATIONAL","The overall goals of this proposal are to determine the genetic architecture of recurrent pregnancy loss (RPL) and to discover genomic predictors of RPL.",[27],"2026-05-20",{"date":36,"type":39},{"date":67,"type":39},"2021-09-01",{"date":69,"type":21},"2026-12",{"name":71,"class":72},"Yale University","OTHER",10,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":106},"100636149","effects-of-high-frequency-left-dorsolateral-prefrontal-rtms-on-heart-brain-coupling-in-women-with-recurrent-pregnancy-loss-and-elevated-bmi-100636149","NCT07561931","Effects of High-frequency Left Dorsolateral Prefrontal rTMS on Heart-brain Coupling in Women With Recurrent Pregnancy Loss and Elevated BMI","Effects of High-frequency Left Dorsolateral Prefrontal rTMS on Heart-brain Coupling in Women With Recurrent Pregnancy Loss and Elevated BMI: a Randomized, Sham-controlled Mechanistic Trial (NEURO-CARD-BMI)","NEURO-CARD-BMI","Inclusion Criteria:\n\n* 1.Female participants aged 18-45 years and right-handed.\n* 2.Fulfillment of the prespecified definition of recurrent pregnancy loss in this study, defined as at least two consecutive spontaneous miscarriages occurring before 28 weeks of gestation.\n* 3.BMI ≥24 kg\u002Fm², classified as overweight or obesity according to the Chinese adult criteria for overweight and obesity.\n* 4.Currently not pregnant and in a clinically stable condition. If there is a recent history of missed abortion, appropriate management must have been completed and obstetric assessment must confirm the absence of acute vaginal bleeding, infection, marked abdominal pain, or hemodynamic instability.\n* 5.Ability to understand the study procedures, provide written informed consent, and cooperate with scale assessment, transcranial magnetic stimulation safety screening, and the single-session rTMS-ECG protocol.\n\nExclusion Criteria:\n\n* 1.Presence of contraindications to transcranial magnetic stimulation or elevated seizure risk, including but not limited to epilepsy or a history of unexplained seizures, intracranial ferromagnetic metal implantation, or the presence of electronic or metallic implanted devices within 30 cm of the coil that are judged unsuitable for transcranial magnetic stimulation.\n* 2.Current pregnancy.\n* 3.Hemodynamic instability or cardiovascular abnormalities that may substantially affect interpretation of the primary endpoint, including systolic blood pressure \\>180 mmHg or \\\u003C90 mmHg, atrial fibrillation or other clinically significant arrhythmias, valvular heart disease, marked sinus bradycardia, symptomatic coronary artery disease, or other cardiovascular conditions judged by the research team to make participation unsuitable.\n* 4.Uncontrolled major medical or neurologic disorders, particularly those that may substantially affect autonomic state, ECG recording, or interpretation of the primary endpoint, including uncontrolled thyroid dysfunction, uncontrolled diabetes mellitus, significant cerebrovascular disease, neurologic disorders, or active pulmonary disease.\n* 5.Presence of significant suicide risk.\n* 6.Severe psychiatric disorders that may affect study safety or adherence, including schizophrenia spectrum disorders, bipolar disorder during a manic or hypomanic episode, delirium, and active substance use disorder.\n* 7.Severe anxiety or severe depression, defined as a Hamilton Anxiety Rating Scale total score of ≥25 or a 17-item Hamilton Depression Rating Scale total score of ≥24.\n* 8.Recent medication-related confounding risk, including current withdrawal from alcohol, sedative-hypnotics, or other relevant substances, or initiation, discontinuation, or dose adjustment within the preceding 2 weeks of medications that may substantially affect seizure threshold, autonomic function, ECG-related indices, or interpretation of the primary endpoint.\n* 9.Any other condition judged by the research team to make participation inappropriate.",{"count":83,"type":21},60,[24],"This randomized, sham-controlled mechanistic trial will examine whether a single session of high-frequency repetitive transcranial magnetic stimulation, rTMS, applied to the left dorsolateral prefrontal cortex can modify heart-brain coupling in women with recurrent pregnancy loss and elevated body mass index, BMI. Women with recurrent pregnancy loss often experience reproductive, metabolic, and emotional stress at the same time, and this combined vulnerability may be associated with altered autonomic regulation and exaggerated cardiac responses to stress. The left dorsolateral prefrontal cortex is a key brain region involved in cognitive control, emotion regulation, and top-down modulation of autonomic function.\n\nEligible participants will be randomly assigned in a 1:1 ratio to receive either real or sham rTMS at the same left dorsolateral prefrontal target. The stimulation protocol will use 10 Hz rTMS at 100% motor threshold, delivered in 30 cycles of 5 s stimulation followed by 11 s inter-train interval, with simultaneous 3-lead electrocardiography recording. The primary endpoint will be the between-group difference in mean heart-brain coupling across 30 stimulation cycles. Safety and tolerability will also be monitored. This study is intended to provide mechanistic evidence and methodological support for future multi-session randomized trials in this population.",[27,87,88],"Overweight , Obesity","Heart-Brain Coupling",[90,91,92,93,32,94,95],"recurrent pregnancy loss","elevated BMI","overweight","heart-brain coupling","left dorsolateral prefrontal cortex","autonomic regulation","NOT_YET_RECRUITING","2026-04-24",{"date":99,"type":39},"2026-05-01",{"date":101,"type":21},"2026-04-28",{"date":103,"type":21},"2026-09-30",{"name":105,"class":72},"Shenyang Medical College",1,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":136},"100617957","cardiac-autonomic-and-anxiety-regulation-via-closed-loop-neurofeedback-in-recurrent-pregnancy-loss-100617957","NCT07325370","Cardiac Autonomic and Anxiety Regulation Via Closed-loop nEurofeedback in Recurrent Pregnancy Loss","Right Dorsolateral Prefrontal Cortex-Targeted fNIRS-BCI Closed-loop Neurofeedback for Anxiety Relief and Cardiac Autonomic Regulation in Women With Recurrent Pregnancy Loss: a Randomized, Sham-controlled Clinical Trial","CARE-RPL","Inclusion Criteria:\n\n* (i) Women aged 18-45 years, right-handed;\n* (ii) Diagnosis of recurrent pregnancy loss (RPL), defined as ≥2 consecutive spontaneous pregnancy losses occurring before 28 weeks of gestation;\n* (iii) Not currently pregnant, or currently in a missed miscarriage state;\n* (iv) Meet DSM-5 diagnostic criteria for an anxiety disorder, with at least moderate severity, defined as Clinical Global Impression-Severity (CGI-S) ≥4;\n* (v) Hamilton Anxiety Rating Scale (HAMA) ≥16, with 17-item Hamilton Depression Rating Scale (HAMD-17) \\\u003C17, to ensure anxiety is the predominant affective disturbance.\n\nExclusion Criteria:\n\n* (i) Markedly unstable blood pressure (systolic BP \\>180 mmHg or \\\u003C90 mmHg);\n* (ii) Clinically important comorbid organic diseases, including but not limited to hyperthyroidism, history of atrial fibrillation, sinus bradycardia, major neurological disorders, cerebrovascular disease, or severe pulmonary disease;\n* (iii) Significant suicide risk, judged by psychiatric assessment to be unsuitable for study participation;\n* (iv) Other severe psychiatric disorders, including substance use disorder, schizophrenia, delusional disorder, unspecified psychotic disorder, bipolar disorder, or delirium;\n* (v) Use of any oral antidepressant, anxiolytic, or antipsychotic medication within the past 4 weeks, or fluoxetine within the past 6 weeks, or any long-acting injectable antipsychotic within the past 3 months.",{"count":116,"type":21},62,[24],"The goal of this clinical trial is to learn whether right dorsolateral prefrontal cortex (right DLPFC)-targeted fNIRS-BCI online closed-loop neurofeedback, delivered with slow-wave acoustic cueing, can reduce anxiety symptoms and improve cardiac autonomic regulation in women with recurrent pregnancy loss (RPL) and comorbid anxiety (women aged 18-45 years, right-handed, currently not pregnant or in a missed miscarriage state).\n\nThe main questions it aims to answer are:\n\nDoes real neurofeedback increase the proportion of participants who achieve an anxiety treatment response (defined as ≥50% reduction in Hamilton Anxiety Rating Scale \\[HAMA\\] total score from baseline) compared with sham feedback, at end of treatment and at 3-month follow-up? Is the intervention safe and well tolerated, as reflected by between-group differences in adverse events during the training period? Do brain and autonomic measures show between-group differences during the first formal session, including right DLPFC HbO downregulation, interhemispheric DLPFC synchronisation, heart rate (HR), and heart rate variability (HRV) indices? Researchers will compare real right DLPFC neurofeedback to sham feedback (identical procedures and displays but weakened coupling to real-time neural activity) to see if real neurofeedback improves anxiety outcomes and brain-heart autonomic regulation.\n\nParticipants will:\n\nComplete screening, baseline clinical assessments, and physical examination Be randomly assigned (1:1) to real neurofeedback or sham feedback Complete 3 days of adaptation training followed by 3 weeks of training (15 sessions; one weekday session per day; \\~20 minutes each) using a block design with slow-wave acoustic cueing (1 Hz amplitude-modulated tone; 20 s rest + 40 s cueing per block; 20 blocks\u002Fsession) Undergo fNIRS recording in all sessions, with ECG recorded in session 1 only (for HR\u002FHRV analyses) Receive matched, guideline-informed cognitive-behavioural therapy (CBT) during the intervention period Complete anxiety-related assessments at baseline, \\~1 hour after the final session, and 3 months after treatment, with adverse events monitored throughout the intervention period",[27,120],"Anxiety",[30,122,123,124,125,126,127,128],"Anxiety disorders","Right dorsolateral prefrontal cortex","Functional near-infrared spectroscopy","Brain-computer interface","Closed-loop neurofeedback","Cardiac autonomic function","Brain-heart coupling","2026-04-21",{"date":97,"type":39},{"date":132,"type":39},"2025-12-29",{"date":134,"type":21},"2026-10-30",{"name":105,"class":72},2,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":144,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":147,"briefSummary":148,"conditions":149,"keywords":152,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":4},"100634662","effect-of-comprehensive-spa-rehabilitation-on-female-infertility-a-clinical-study-in-adult-women-infertility-spa-100634662","NCT07542600","Effect of Comprehensive Spa Rehabilitation on Female Infertility: A Clinical Study in Adult Women (Infertility-Spa)","Objective Assessment of the Effect of Comprehensive Spa Rehabilitation Care on Female Infertility: A Prospective Interventional Clinical Study","Inclusion Criteria:\n\n* Female, age 20-40 years\n* Diagnosis of infertility (primary or secondary)\n* History of at least one unsuccessful embryo transfer\n\nExclusion Criteria:\n\n* Contraindications to spa treatment\n* Acute gynecological inflammation\n* Severe comorbidities affecting study outcomes\n* Oncological disease\n* Alcohol intake \\>20 g\u002Fday\n* Non-compliance with treatment\n* Diagnosed with endometriosis","20 Years","40 Years",{"count":20,"type":21},[24],"This is a prospective, single-arm, pretest-posttest study evaluating the effects of a 21-day comprehensive spa treatment (Komplexní lázeňská léčebně rehabilitační péče, KLP) on female infertility at spa facility in Františkovy Lázně, Czech Republic.\n\nThe study enrolls 55 women aged 20-40 years diagnosed with infertility. The primary objective is to assess changes in hormonal profile before and after treatment.\n\nSecondary objectives include evaluation of body composition, psychometric outcomes and long-term reproductive outcomes.",[150,151,27],"Female Infertility","Reproductive Disorders",[153,154,150,155,156],"Spa Treatment","Balneotherapy","Hormonal Profile","IVF Preparation","2026-04-17",{"date":129,"type":39},{"date":160,"type":21},"2026-04-15",{"date":162,"type":21},"2028-01-01",{"name":164,"class":72},"Institute of Spa and Balneology, public research institution",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":22,"phases":174,"briefSummary":175,"conditions":176,"keywords":177,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":106},"100530138","tender-loving-care-for-recurrent-pregnancy-loss-100530138","NCT06182878","Tender Loving Care for Recurrent Pregnancy Loss","A Single-arm Trial of a Web Based TLC (Tender Loving Care) Platform to Psychologically Support Patients With Recurrent Pregnancy Loss","Inclusion Criteria:\n\n* Pregnant individuals receiving their prenatal care at WRNMMC\n* Able to speak and understand English\n* Less than or equal to 10+0 weeks gestation by last menstrual period (LMP) or dating ultrasound at the time of enrollment\n* At least two prior pregnancy losses. Pregnancy losses must be confirmed with laboratory criteria confirming a positive pregnancy test in the military electronic medical record with subsequent resolution (resolution may be reported by patient), or with ultrasound criteria demonstrating an intrauterine gestational sac with subsequent resolution (resolution may be reported by patient).\n\nExclusion Criteria:\n\n* Age less than 18 years and older than 44 at time of enrollment\n* Unable to speak or understand English\n* Current smoker or tobacco use within 30 days\n* History of uterine anomaly, coagulopathy, balanced translocation, endometrial polyps, submucosal fibroids, pathology confirmed acute or chronic endometritis, hydrosalpinx, history of Asherman syndrome, poorly controlled endocrinopathies, HIV infection\n* History of gonadotoxic therapy or cancerous condition of the female reproductive tract\n* Suspicion for or confirmation of an ectopic pregnancy","44 Years",{"count":83,"type":21},[24],"The goal of this investigational study is to evaluate participation in a weekly, interactive, tender loving care messaging platform impact on pregnancy outcomes in patients with recurrent pregnancy loss.\n\nThe main questions it aims to answer are: (1) does participation in weekly, interactive tender loving care messages increase live birth rates in patients with recurrent pregnancy loss? (2) Does participation in weekly, interactive tender loving care messages increase patients' quality of life? Does participation in weekly, interactive tender loving care messages decrease patients' depressive symptoms?\n\nParticipants will be asked to interact with weekly messages providing prenatal counseling and support. Additionally, patients will be asked to complete the fertility quality of life survey several times over the course of the pregnancy.",[27],[27],{"date":179,"type":39},"2026-04-22",{"date":181,"type":39},"2024-01-01",{"date":183,"type":21},"2026-12-01",{"name":185,"class":186},"Walter Reed National Military Medical Center","FED",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":195,"enrollmentInfo":196,"targetDuration":4,"studyType":22,"phases":198,"briefSummary":199,"conditions":200,"keywords":207,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":106},"100613355","study-of-endometrial-immune-and-microbiological-modifications-in-cases-of-recurrent-implantation-failure-andor-recurrent-pregnancy-loss-100613355","NCT07265505","Study of Endometrial Immune and Microbiological Modifications in Cases of Recurrent Implantation Failure and\u002For Recurrent Pregnancy Loss","Study of Immune and Microbiological Modifications of the Endometrium in Cases of Recurrent Implantation Failure and\u002For Recurrent Pregnancy Loss","IMERR","Inclusion Criteria:\n\n* Female aged ≥18 and \\\u003C36 years\n* Undergoing assisted reproductive technology (ART) in a fertility center\n* Covered by the French national health insurance system\n* Belonging to one of two groups:\n\n  * Study group: history of recurrent implantation failure (RIF) and\u002For recurrent pregnancy loss (RPL)\n  * Control group: no history of RIF or RPL\n\nExclusion Criteria:\n\n* Pregnant at inclusion\n* Refusal to provide written informed consent\n* Antibiotic use within one month prior to endometrial biopsy Positive serology for hepatitis B, hepatitis C or HIV\n* Uterine anatomical abnormalities (e.g., polyps, cavity-distorting fibroids, untreated hydrosalpinx)\n* Known chromosomal abnormality in either partner\n* Known autoimmune disease, thrombophilia, or antiphospholipid antibody syndrome\n* Persons under legal protection (e.g., guardianship, curatorship)","35 Years",{"count":197,"type":21},100,[24],"The IMERR study aims to improve understanding of certain causes of infertility related to recurrent implantation failure (RIF) and\u002For recurrent pregnancy loss (RPL), conditions that affect many women undergoing assisted reproductive technology (ART). Despite medical advances, some patients repeatedly fail to achieve pregnancy, or experience repeated miscarriages. These situations may be linked to subtle immune or microbial disturbances in the uterus. This study seeks to identify immune and microbiological profiles in the endometrium during the implantation window-a crucial period when the embryo attaches to the uterine wall. We will compare women who have experienced RIF and\u002For RPL with women who have had no such history. Blood and uterine samples will be analyzed to investigate whether certain immune or microbial features are associated with these reproductive failures. The ultimate goal is to uncover predictive factors that may explain why some women experience implantation failure or pregnancy loss, and to lay the foundation for future personalized treatments to improve reproductive outcomes.",[201,27,202,203,204,205,206],"Recurrent Implantation Failure","Infertility, Female","Endometrial Diseases","Endometritis","Endometriosis","Adenomyosis",[208,209,210,211,212,213,214,215,216,206,205],"Uterine Immune Profile","Endometrial Receptivity","Infertility","Recurrent Miscarriage","IVF Failure","Implantation Window","Reproductive Immunology","Endometrial Microbiome","Chronic Endometritis","2026-02-03",{"date":219,"type":39},"2026-02-05",{"date":221,"type":21},"2026-04",{"date":223,"type":21},"2031-04",{"name":225,"class":72},"Assistance Publique - Hôpitaux de Paris",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":233,"enrollmentInfo":234,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":235,"conditions":236,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":106},"100452287","association-between-plasma-level-of-mannose-binding-lectin-and-human-reproduction-100452287","NCT05169541","Association Between Plasma Level of Mannose Binding Lectin and Human Reproduction","Is Plasma Level of Mannose Binding Lectin Associated With Reproductive Failure?","Inclusion Criteria:\n\nfulfil one of the following:\n\n* 3 consecutive pregnancy losses after spontaneous conception\n* 3 consecutive pregnancy losses after assisted reproductive technology treatment (ART) including IVF, ICSI and FET\n* 3 failed embryo transfers characterized by no achieved pregnancy (after 3 cycles with minimum 1 embryo transfer of a good-quality embryo in each cycle.)\n\nExclusion Criteria:\n\n* Age \\\u003C18 or \\>45 years\n* AMH \\\u003C4.0 pmol\u002Fl unless donor egg in previous cycles\n* Significant uterine malformation\n* Known endometrial pathologies including intrauterine endometriosis, adenomyosis, hyperplasia or polyps\n* Known chromosomal abnormalities\n* Pregnancy \\>9 weeks of gestation at the time collecting the blood sample","41 Years",{"count":60,"type":21},"A low plasma level of mannose binding lectin (p-MBL) is associated with unexplained recurrent pregnancy loss (RPL), but it is not investigated if it is associated with unexplained reproductive failure in general, including recurrent implantation failure (RIF) after assisted reproductive technology (ART) (including IVF, ICSI and FET), recurrent pregnancy loss (RPL) after spontaneous conception, and RPL after ART.",[237,27,201,210,238,211,239],"Mannose-Binding Lectin Deficiency","Habitual Abortion","Recurrent Spontaneous Abortion","2025-11-20",{"date":242,"type":39},"2025-11-24",{"date":244,"type":39},"2016-01-01",{"date":246,"type":21},"2026-11-30",{"name":248,"class":72},"Aalborg University Hospital",{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":11,"sex":16,"minAge":144,"maxAge":145,"enrollmentInfo":257,"targetDuration":4,"studyType":22,"phases":259,"briefSummary":260,"conditions":261,"keywords":263,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":136},"100566202","effect-of-hcq-combined-with-lt4-on-lbr-in-euthyroid-women-with-urpl-and-tpo-ab-100566202","NCT06652113","Effect of HCQ Combined With LT4 on LBR in Euthyroid Women With URPL and TPO-Ab","The Efficacy of Hydroxychloroquine Combined With Levothyroxine in Euthyroid Women With Thyroid Antibody Positive and Unexplained Recurrent Pregnancy Loss：A Multicenter, Randomized Controlled Study","QT-LIFE","Inclusion criteria:\n\n1. Women with history of two or more pregnancy loss with the same male partner (including biochemical pregnancies).\n2. Karyotype analyses show no pathological abnormalities in each individual of the recruited couple.\n3. Women aged between 20 and 40 years old (including 20 and 40).\n4. Lupus anticoagulant (LA), anticardiolipin antibody (ACA), and anti-beta2-glycoprotein I antibodies (anti-β2-GP1 Ab) tests are all negative.\n5. It is confirmed by ultrasound or hysteroscopy that there are no pathological lesions that affect the morphology of the uterine cavity (such as submucosal uterine fibroids, uterine malformations).\n6. TPO-Ab positive (TPO-Ab \\> 60 IU\u002FmL using the Siemens kit of electrochemiluminescence method, or TPO-Ab \\> 34 IU\u002FmL using the Roche kit of chemiluminescence method).\n7. Biochemically euthyroid. TSH, free triiodothyronine (FT3), and free thyroxine (T4) are all within the reference range of corresponding laboratory testing in each research center.\n\nExclusion criteria:\n\n1. Rheumatic diseases, such as systemic lupus erythematosus, undifferentiated connective tissue disease, etc.\n2. Metabolic or endocrine diseases, such as diabetes.\n3. Abnormal renal function: plasma creatinine level ≥130 μmol\u002FL or abnormal liver function: alanine aminotransferase ≥80U\u002FL or aspartate aminotransferase ≥80U\u002FL.\n4. Hypertension and malignant tumors.\n5. Under treatment with glucocorticoids or immunosuppressor, including cyclosporine, azathioprine, prednisone, and methylprednisolone.\n6. Body Mass Index (BMI) \\>28kg\u002Fm2.\n7. Past history of hyperthyroidism, hypothyroidism, and thyroid malignant tumors;\n8. Allergy to 4-aminoquinoline compound, or those with retinal or visual field lesions caused by 4-aminoquinoline compound.",{"count":258,"type":21},796,[24],"The goal of this clinical trial is to learn if combined treatment of levothyroxine and hydroxychloroquine would improve the live birth of euthyroid women with thyroid peroxidase antibodies and unexplained recurrent pregnancy loss.\n\nResearchers will compare combined treatment of levothyroxine and hydroxychloroquine to a treatment of levothyroxine alone to see if combined treatment works to improve live birth of euthyroid participants with thyroid peroxidase antibodies and unexplained recurrent pregnancy loss.\n\nParticipants will:\n\n* Receive combined treatment of levothyroxine and hydroxychloroquine or treatment of levothyroxine alone every day at least 8 weeks before pregnancy, and continue their treatment till the end of pregnancy.\n* Visit the clinic 4 weeks and 8 weeks after their treatments, and every 12 weeks before they get pregnant for checkups and tests. During their pregnancy, they will visit the clinic before gestation of 12 weeks, and will be followed up with phone call in the second trimester and after parturition.",[27,262],"Euthyroid With Thyroid Antibodies",[264,265,266,90],"live birth","euthyroid","thyroid peroxidase antibody","2025-09-17",{"date":269,"type":39},"2025-09-23",{"date":271,"type":39},"2024-11-15",{"date":273,"type":21},"2037-03",{"name":275,"class":72},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":277,"slug":278,"hasResults":11,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":16,"minAge":283,"maxAge":284,"enrollmentInfo":285,"targetDuration":287,"studyType":61,"phases":4,"briefSummary":288,"conditions":289,"keywords":290,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":106},"100515259","prospective-recurrent-pregnancy-loss-registry-100515259","NCT05989178","Prospective Recurrent Pregnancy Loss Registry","Prospective Recurrent Pregnancy Loss (ProRPL) Registry","Inclusion Criteria:\n\n• Patients seen at the BC Women's Recurrent Pregnancy Loss Clinic with recurrent pregnancy loss, defined as ≥2 pregnancy losses before 20 weeks of gestation.\n\nExclusion Criteria:\n\n• Patients at BC Women's Recurrent Pregnancy Loss Clinic seen for reasons other than recurrent pregnancy loss.","15 Years","49 Years",{"count":286,"type":21},3000,"5 Years","The purpose of this Registry is to prospectively collect data of Recurrent Pregnancy Loss (RPL) patients attending the specialized care centre at the BC Women's Hospital, in order to evaluate investigation practices, treatment options, and outcomes for this patient population over time.",[27],[30,291,292,293,294],"Unexplained","Explained","Miscarriage","Live Birth","2024-12-09",{"date":297,"type":39},"2024-12-13",{"date":299,"type":39},"2022-07-12",{"date":301,"type":21},"2032-12-31",{"name":303,"class":72},"University of British Columbia",{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":145,"enrollmentInfo":312,"targetDuration":4,"studyType":22,"phases":314,"briefSummary":316,"conditions":317,"keywords":319,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":106},"100495002","phase-4-prednisolone-administration-in-patients-with-unexplained-recurrent-miscarriages-100495002","NCT05725512","Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages","Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages, PREMI Trial","PREMI","Inclusion Criteria:\n\nIn order to be eligible to participate in this study, a subject must meet all of the following criteria:\n\n* Unexplained recurrent pregnancy loss: defined as the loss of ≥2 pregnancies, without any known cause for RM (parental chromosomal abnormalities, uterine anomalies, acquired or hereditary thrombophilia, endocrine diseases (such as hypothyroidism or diabetes)).\n* The miscarriages include:\n\n  * all consecutive or non-consecutive pregnancy losses before the 24th week of gestation verified by ultrasonography or uterine curettage and histology\n  * non-visualized pregnancies (including biochemical pregnancy losses and\u002For resolved and treated pregnancies of unknown location), verified by positive urine or serum hCG Ectopic and molar pregnancies are not included\n* Age 18 - 39 years at randomization (likelihood of miscarriages due to chromosomal aberrations is higher when age \\> 39 years. Such miscarriages are unlikely to be pre-vented by prednisolone therapy)\n* Conception confirmed by urinary pregnancy test, with estimated gestational age ≤ 7weeks\n* Willing and able to give informed consent in English or Dutch (IC)\n\nExclusion Criteria:\n\nA potential subject who meets any of the following criteria will be excluded from participation in this study:\n\n* Any of the following diagnosis for the recurrent miscarriages\n\n  * Antiphospholipid syndrome (lupus anticoagulant and\u002F or anticardiolipin anti-bodies and\u002For beta-2 glycoprotein \\[IgG or IgM)\n  * Congenital uterine abnormalities (as assessed by 2D or 3d ultrasound, hys-terosonography, hysterosalpingogram or hysteroscopy)\n  * Abnormal parental karyotype\n* Instable or exacerbation of auto-immune diseases such as diabetes, thyroid disease, inflammatory bowel diseases or SLE\n* Inability to conceive within 1 year of recruitment\n* Current treatment with systemic prednisolone or other immune suppressive medication (for any indication)\n* Previous enrolment in the PREMI trial\n* Enrolment in any other trial that studies the effectiveness of an intervention on RM\n* Contraindications to prednisolone use:\n\n  * Known allergy for prednisolone\n  * Acute bacterial infection or parasite infection\n  * Active COVID infection\n  * Systemic sclerosis\n  * Ulcus ventriculi or ulcus duodeni in medical history\n  * Obesity with BMI \\>40\n* Some drugs are known to interact with Prednisolone, and thus women on the following drugs are not eligible to take part in the PREMI trial:\n\n  * Enzyme inducers, such as carbamazepine, fenobarbital, fenytoïne and ri-fampicine\n  * CYP3A inhibitors, such as Cobicistat or Ritonavir\n  * Cyclosporine\n  * Digoxin\n  * Vaccination (with inactivated virus or bacteria) during prednisolone use is possibly less effective",{"count":313,"type":21},490,[315],"PHASE4","Recurrent miscarriages (RM) affects 3% of all fertile couples, but remains unexplained in most cases, limiting therapeutic options. Possibly the maternal immune system plays a role in recurrent miscarriage. Prednisolone suppresses the immune system and might enable development of normal pregnancy.\n\nIn this randomized controlled clinical trial the investigators will study the effect of prednisolone on the live birth rate in patients with RM. Secondary, the tolerability and safety for mother and child and the cost-effectiveness is investigated.\n\nIn the study one group of pregnant women with RM and gestational age \\\u003C7 weeks will receive prednisolone, the other group will receive a placebo. Total use of the medicine during this study is 8 weeks, further care during the study is routinely antenatal care. Subjects will be asked to fill in 4 short questionnaires and will have contact with a research nurse at different time points to gain information on the course of the pregnancy and possible side effects.\n\nResults of the study will be implemented in (inter) national guidelines, to effect everyday practice.",[211,27,238,293,318],"Fertility Disorders",[30,320,321],"Recurrent miscarriage","prednisolone","2024-05-23",{"date":324,"type":39},"2024-05-24",{"date":326,"type":39},"2024-01-29",{"date":328,"type":21},"2027-07-29",{"name":330,"class":72},"Leiden University Medical Center",{"id":332,"slug":333,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":337,"eligibilityCriteria":338,"healthyVolunteers":11,"sex":57,"minAge":17,"maxAge":339,"enrollmentInfo":340,"targetDuration":342,"studyType":61,"phases":4,"briefSummary":343,"conditions":344,"keywords":345,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":4},"100452154","on-pregnancy-after-losses---opal-study-100452154","NCT05167812","On Pregnancy After Losses - OPAL Study","On Pregnancy After Losses; Predicting Pregnancy Success in Couples With Recurrent Pregnancy Loss","OPAL","Inclusion Criteria:\n\nCouples that fulfill the following criteria are included (according to the ESHRE Recurrent Pregnancy Loss Guideline 2017):\n\n* RPL in the current relationship: defined as the loss of ≥ 2 preceding pregnancies. These pregnancy losses include:\n\n  * all pregnancy losses before the 24th week of gestation verified by ultrasonography or uterine curettage and histology\n  * non-visualized pregnancies (including biochemical pregnancy losses and\u002For resolved and treated pregnancies of unknown location), verified by positive urine or serum hCG\n  * both consecutive and non-consecutive pregnancy losses\n* Dutch or English speaking couple\n* Couples with females aged ≤42 years at intake\n\nExclusion Criteria:\n\n* Mental or legal incapability of either the male or female of the couple\n* Loss of \\\u003C 2 pregnancies in current relationship","42 Years",{"count":341,"type":21},1931,"3 Years","Rationale:\n\nRecurrent pregnancy loss (RPL) is defined as the loss of two or more conceptions before the fetus reaches viability. It affects 1-3% of all fertile couples and despite extensive diagnostic work-up, in only around 30% an underlying cause is identified. Several factors may increase the risk for miscarriage, but the chance of a normal, successful pregnancy is still high. So, in supporting couples with RPL, an important part of the clinical management of these couples is to provide couples with accurate prognoses for their next pregnancy. The main limitation in current prediction models is the lack of a sufficiently large cohort, adjustment for relevant risk factors such that prognoses are individualized, and separating between the cumulative live birth rate and the chance that the next conception will lead to a live birth. In this project therefore we aim to make an individualized prognosis regarding the future chance of live birth and the chance of a healthy child. This could then lead to improved wellbeing and the ability of making future reproductive choices.\n\nObjectives:\n\nPrimary objective: to predict the chance of a live birth within three years after intake in couples with unexplained RPL\n\nSecondary objectives:\n\n* to predict the chance of an ongoing pregnancy (\\>12 weeks) in the next pregnancy in couples with unexplained RPL.\n* to predict the chance of a complicated pregnancy in couples with unexplained RPL\n* to predict the chance dynamically of a live birth given the outcome of a pregnancy after intake\n* to predict the chance of above outcomes in couples with a known cause for RPL\n\nStudy design: A multicenter retrospective and prospective cohort study.\n\nStudy population:\n\nCouples with females aged ≤42 years in both prospective and retrospective inclusion.\n\nRetrospective inclusion: Couples with RPL who visited the RPL outpatient clinic in participating centers from 2006 until the start of this study.\n\nProspective inclusion: new couples with RPL who will visit the clinic from 2021 onwards.\n\nMain study parameters\u002Fendpoints:\n\n* Pregnancy outcomes since intake\n* Time to pregnancy since intake\n* Time between pregnancies since intake\n* Pregnancy complications since intake\n* All outcomes will be obtained up to a maximum of five years after intake\n* Patient characteristics: cause for RPL, female age, male age, previous live birth, duration of RPL (since diagnosis)\n\nNature and extent of the burden and risks associated with participation, benefit and group relatedness:\n\nParticipating in this study does not yield any risks. There could be a burden in case of retrospectively collecting data. Participating does not yield direct benefits for the subjects, however it may lead to future improvements of care for couples with RPL.",[27],[346,347,348,349],"Prediction","Prognosis","Live birth","Pregnancy success chance","2021-12-21",{"date":352,"type":39},"2021-12-22",{"date":354,"type":21},"2022-02-01",{"date":356,"type":21},"2028-02-01",{"name":330,"class":72}]